Information  X 
Enter a valid email address

Antisoma PLC (SRC)

  Print      Mail a friend       Annual reports

Thursday 13 December, 2001

Antisoma PLC

US Patent Approval

Antisoma PLC
13 December 2001


                    Antisoma receives US patent for Therex

13 December 2001, London, UK - Antisoma plc (LSE:ASM, NASD:ASOM), the UK-based
biopharmaceutical company specialising in the development of products for the
treatment of cancer, today announces that it has received notification of the
granting of a US patent for Therex, which is currently in Phase I studies for
the treatment of breast cancer.

Therex is a naked humanised antibody which attaches itself to cancer cells. It
helps components of the immune system, including natural killer cells, to find
and destroy the cancer cells.  The antibody recognizes MUC1, a cytokine-like
receptor which is highly expressed by most solid tumours.

The US patent covers antibodies that contain specified amino acid sequences
and that recognise MUC1.  The US patent will provide protection to Therex
until at least 2018.

Therex is initially being developed to treat women with breast cancer who have
relapsed following first line treatment. Breast cancer is the second most
common form of cancer, with around 500,000 women diagnosed with the disease
each year in North America, Europe and Japan.

Glyn Edwards, Chief Executive Officer of Antisoma, commented:

'The granting of the US patent for Therex is a further important strengthening
of our intellectual  property position. Therex is a highly promising approach
to the treatment of cancer, which is generating a lot of interest from
potential partners.'

Enquiries:

Antisoma plc
Glyn Edwards, Chief Executive Officer           Tel: +44 (0)20 8799 8200

Financial Dynamics
Jonathan Birt                                   Tel: +44 (0)20 7831 3113

Except for the historical information presented, certain matters discussed in
this statement are forward looking statements that are subject to a number of
risks and uncertainties that could cause actual results to differ materially
from results, performance or achievements expressed or implied by such
statements. These risks and uncertainties may be associated with product
discovery and development, including statements regarding the company's
clinical development programmes, the expected timing of clinical trials and
regulatory filings. Such statements are based on management's current
expectations, but actual results may differ materially.

Notes to Editors

Antisoma

Antisoma is a biopharmaceutical company developing novel products for the
treatment of cancer. Using its drug development experience, the Company aims
to produce safer and more effective tumour targeting therapies for
commercialisation by pharmaceutical partners. Antisoma acquires the rights to
promising new product candidates through partnerships with internationally
recognised academic or cancer research institutions. These include the lead
product candidate, pemtumomab, which was licensed from the Imperial Cancer
Research Fund and is currently in a Phase III study as adjuvant treatment for
ovarian cancer, with designated Orphan Drug status in the US and EU. There are
three additional products in the clinical pipeline, Therex, DMXAA and
TheraFab, and several pre-clinical programmes of which two, Angiomab and
Thioplatin, are expected to enter clinical studies in 2002. Visit
www.antisoma.com for further information about Antisoma.

Therex

Nearly 500,000 women are diagnosed with breast cancer every year in North
America, Europe and Japan. Therex, based on a humanised form of the pemtumomab
monoclonal antibody, is under development initially to treat women with breast
cancer who have relapsed following first line treatment. The antibody targets
most epithelial cancer cells and since many breast cancers are epithelial,
Antisoma estimates that Therex could treat over 112,000 cases annually. This
would indicate a total market potential in excess of US$1 billion.

The Breast Cancer Biology Group at Guy's Hospital, funded by the ICRF who
originally developed Therex, conducted a Phase I clinical study to test the
product's safety and tolerability following repeat administration. Results
from 18 patients following treatment for primary breast cancer indicate that
the drug is well tolerated at the doses given. Antisoma is now progressing
Therex into the next Phase of clinical development and has contracted with
Lonza to provide clinical-grade material for the study, expected to start in
2002.